According to @mcuban, Cost Plus Drugs lowers consumer drug prices only when the company’s acquisition cost declines, because it passes through cost reductions with a standard markup, charges everyone the same price, and has no membership fees, source: @mcuban on Twitter, Dec 7, 2025, https://twitter.com/mcuban/status/1997732468162449641. @mcuban states Cost Plus Drugs is the only company that publishes a full price list, enabling direct visibility into any future price changes and markup structure, source: @mcuban on Twitter, Dec 7, 2025, https://twitter.com/mcuban/status/1997732468162449641. @mcuban contrasts this approach with insurance companies and hospitals, saying they do not operate under the same transparent, uniform-pricing model, underscoring structural differences in healthcare pricing, source: @mcuban on Twitter, Dec 7, 2025, https://twitter.com/mcuban/status/1997732468162449641. No cryptocurrencies were mentioned and no direct crypto market impact was referenced in the post, source: @mcuban on Twitter, Dec 7, 2025, https://twitter.com/mcuban/status/1997732468162449641.

According to @mcuban, OTC loratadine shows a wide retail price dispersion: Loratadine 10 mg 90 tablets at Cost Plus Drugs is $7.06, while Claritin 10 mg 100 tablets on Amazon is $47.99, and a non-brand OTC option is quoted at $7.99 in the same post (source: @mcuban on X, Dec 6, 2025). According to @mcuban, these figures imply roughly $0.078 per pill for the Cost Plus Drugs generic versus about $0.48 per pill for Amazon’s branded Claritin, quantifying an approximately 6x channel price differential that is directly relevant for price-comparison and retail mix analysis (source: @mcuban on X, Dec 6, 2025). According to @GeBaiDC, once loratadine became OTC, the per-pill cost fell from about $1.10 to about $0.23, and the thread argues that generic drugs should not be covered by insurance, underscoring payer-policy considerations that can shape out-of-pocket purchasing behavior in OTC categories (source: @GeBaiDC thread cited by @mcuban on X, Dec 6, 2025). According to the source, the posts do not mention cryptocurrencies or blockchain, indicating no direct crypto-market catalyst in the cited material (source: @mcuban and @GeBaiDC on X, Dec 6, 2025).

According to @mcuban, Cost Plus Drugs can bring tablet manufacturing of generic OTC and prescription drugs to the United States within about a year if the FDA waives Abbreviated New Drug Application (ANDA) fees, which he quantified as $365,000 per drug and $365 million for 1,000 filings (source: @mcuban on X, Dec 6, 2025). @mcuban stated that ingredients and manufacturing costs are the same for OTC and Rx tablets, enabling sales on CostPlusDrugs.com and TrumpRx at the same or lower prices than overseas-made products if fees are waived (source: @mcuban on X, Dec 6, 2025). @mcuban framed the fee waiver as unlocking domestic competition and lower drug prices via transparency and local manufacturing, contingent on FDA action (source: @mcuban on X, Dec 6, 2025). Dr. Marty Makary stated the FDA will cut red tape to deliver more safe and affordable OTC drugs, indicating regulatory momentum on OTC expansions per his statement (source: @DrMakaryFDA on X, cited by @mcuban, Dec 6, 2025). No direct crypto market linkage or impact on digital assets was cited in these statements (source: @mcuban and @DrMakaryFDA on X, Dec 6, 2025).

According to Mark Cuban on Twitter, Cost Plus Drugs has announced partnerships with several transparent, pass-through pharmacy benefit managers (PBMs), encouraging decision-makers to consult these PBMs before finalizing any corporate pharmacy benefits (Source: @mcuban, May 6, 2025). For investors and trading professionals in the healthcare and pharmaceutical sectors, this move signals a shift towards greater price transparency and potentially lower drug costs, which could impact the stock performance of traditional PBMs and benefit transparency-focused companies.

According to Mark Cuban, there are significant anti-competitive practices by major pharmaceutical members who prevent brand manufacturers from offering rebates through Cost Plus Drugs. Cuban alleges these members threaten to remove manufacturers from formularies if they engage with Cost Plus Drugs. This could impact trading strategies related to pharmaceutical stocks, influencing both market dynamics and investor sentiment.